Scroll Back to Top
Accessibility
Accessibility
Contact Us
OmniSeq

Improving Outcomes for Patients with Solid Tumors

OmniSeq INSIGHT® provides a comprehensive, easy-to-read report with clinical guidance for more precise, targeted therapies and trials for your patients.

How to Order

INSIGHT'S Profiling Empowers
You to Make Better Decisions

From a single tumor biopsy, analyzed by advanced next generation sequencing (NGS) technology,
OmniSeq INSIGHT identifies treatment options in one comprehensive, easy-to-read report.

Icon Profiling

Genomic Profiling

  • 523 Gene NGS Panel
  • Microsatellite instability (MSI) and tumor mutational burden (TMB)
  • DNA and RNA sequencing
  • Single nucleotide variants (SNVs) – insertions/deletions (indels), copy number alterations (CNAs) and fusions
  • Interrogation of full coding regions
  • HLA genotyping
Plus Icon
Immune Profiling Icon

Immune Profiling

  • PD-L1 by immunohistochemistry (IHC)
  • 64 RNA expression/immune profiling genes by immune cycle step:
    • T-cell priming/trafficking
    • T-cell recognition
    • T-cell infiltration
    • Killing cancer cells
    • Cancer testis antigens
Brochure(Opens in a new window) Gene List(Opens in a new window)

Why Choose INSIGHT?

1

Single Tumor Biopsy

A single tissue sample provides complete insight into the tumor and its microenvironment.

vertical separator

2

Pan-Cancer Testing

The report provides comprehensive genomic and immune profiling for all solid tumors.

vertical separator

3

Treatment Options

A summary of FDA-approved therapies, immunotherapies and eligible clinical trials tailored to your patient’s solid tumor.

Identify Approved Drug Candidates

  • Comprehensive Genomics
    • Detects all four main classes of genomic alterations
    • Fusions / splice variants using RNA-Seq hybrid capture
    • Coverage of clinical practice guideline-recommended biomarkers across solid tumor types

Immunotherapy Eligibility

  • Comprehensive Immune Profiling
    • MSI & TMB profiling
    • PD-L1 by IHC
    • Immune biomarker drug targets

Eligible Clinical Trials

  • List of patient-eligible clinical trials within 200 miles of patient’s physical address1

    • Testing for biomarkers with clinical trial associations

Precision Medicine Comparison —
Comprehensive Genomic and Immune Profiling

 ResultLabcorp Oncology
Omniseq INSIGHT		Foundation Medicine® FoundationOne®CDxNeoGenomics® Neotype® Analysis Discovery ProfileCaris MI™ Profile Comprehensive Tumor ProfilingTempus® XT V4
Genomic ProflingNGS for Targeted Therapy523 Genes324 Genes323 Genes700 at High Depth648 Genes
RNA-Seq for Fusion Detection
Yes
No
Add on optionWhole TranscriptomeWhole Transcriptome
Tumor SignaturesTumor Mutational Burden (TMB)
Yes
Yes
Yes
Yes
Yes
Microsatellite Instability (MSI)
Yes
Yes
Yes
Yes
Yes
Tumor Micro-EnvironmentPD-L1 by IHC
Yes
Add on option
Yes
Yes
Add on option
PD-L1/PD-L2 GEP*
Yes
No
No
No
No
CD3/CD8 GEP*
Yes
No
No
No
No
Immune Activation - Gene Expression by RNA-Seq
Yes
No
No
No
No
Tumor Infiltrating Lymphocytes (TILs)
Yes
No
No
No
No
Clinical TrialsGeocoded Clinical Trials for Targeted and Immunotherapy
Yes
Targeted Only
Not Geocoded		Targeted Only
Not Geocoded		Link to CT Connector
(Chemo + Targeted Clinical Trials)		Targeted Only
Geocoded But Not Tumor Specific
  • Genomic Profiling
    Result: NGS for Targeted Therapy
    Labcorp Oncology Omniseq INSIGHT523 Genes
    Foundation Medicine® FoundationOne®CDx324 Genes
    NeoGenomics® Neotype® Analysis Discovery Profile323 Genes
    Caris MI Profile™ Comprehensive Tumor Profiling700 at High Depth
    Tempus® XT V4648 Genes
    Result: RNA-Seq for Fusion Detection
    Labcorp Oncology Omniseq INSIGHT
    Yes
    Foundation Medicine® FoundationOne®CDx
    No
    NeoGenomics® Neotype® Analysis Discovery ProfileAdd on option
    Caris MI Profile™ Comprehensive Tumor ProfilingWhole Transcriptome
    Tempus® XT V4Whole Transcriptome
  • Tumor Signatures
    Result: Tumor Mutational Burden (TMB)
    Labcorp Oncology Omniseq INSIGHT
    Yes
    Foundation Medicine® FoundationOne®CDx
    Yes
    NeoGenomics® Neotype® Analysis Discovery Profile
    Yes
    Caris MI Profile™ Comprehensive Tumor Profiling
    Yes
    Tempus® XT V4
    Yes
    Result: Microsatellite Instability (MSI)
    Labcorp Oncology Omniseq INSIGHT
    Yes
    Foundation Medicine® FoundationOne®CDx
    Yes
    NeoGenomics® Neotype® Analysis Discovery Profile
    Yes
    Caris MI Profile™ Comprehensive Tumor Profiling
    Yes
    Tempus® XT V4
    Yes
  • Tumor Micro-Environment
    Result: PD-L1 by IHC
    Labcorp Oncology Omniseq INSIGHT
    Yes
    Foundation Medicine® FoundationOne®CDxAdd on option
    NeoGenomics® Neotype® Analysis Discovery Profile
    Yes
    Caris MI Profile™ Comprehensive Tumor Profiling
    Yes
    Tempus® XT V4Add on option
    Result: PD-L1/PD-L2 GEP*
    Labcorp Oncology Omniseq INSIGHT
    Yes
    Foundation Medicine® FoundationOne®CDx
    No
    NeoGenomics® Neotype® Analysis Discovery Profile
    No
    Caris MI Profile™ Comprehensive Tumor Profiling
    No
    Tempus® XT V4
    No
    Result: CD3/CD8 GEP*
    Labcorp Oncology Omniseq INSIGHT
    Yes
    Foundation Medicine® FoundationOne®CDx
    No
    NeoGenomics® Neotype® Analysis Discovery Profile
    No
    Caris MI Profile™ Comprehensive Tumor Profiling
    No
    Tempus® XT V4
    No
    Result: Immune Activation - Gene Expression by RNA-Seq
    Labcorp Oncology Omniseq INSIGHT
    Yes
    Foundation Medicine® FoundationOne®CDx
    No
    NeoGenomics® Neotype® Analysis Discovery Profile
    No
    Caris MI Profile™ Comprehensive Tumor Profiling
    No
    Tempus® XT V4
    No
    Result: Tumor Infiltrating Lymphocytes (TILs)
    Labcorp Oncology Omniseq INSIGHT
    Yes
    Foundation Medicine® FoundationOne®CDx
    No
    NeoGenomics® Neotype® Analysis Discovery Profile
    No
    Caris MI Profile™ Comprehensive Tumor Profiling
    No
    Tempus® XT V4
    No
  • Clinical Trials
    Result: Geocoded Clinical Trials for Targeted and Immunotherapy
    Labcorp Oncology Omniseq INSIGHT
    Yes
    Foundation Medicine® FoundationOne®CDxTargeted Only
    Not Geocoded
    NeoGenomics® Neotype® Analysis Discovery ProfileTargeted Only
    Not Geocoded
    Caris MI Profile™ Comprehensive Tumor ProfilingLink to CT Connector
    (Chemo + Targeted Clinical Trials)
    Tempus® XT V4Targeted Only
    Geocoded But Not Tumor Specific

*GEP - genomic expression profiling
Data as of June 16, 2021

Patient Reports: Concise, Comprehensive & Actionable

Comprehensive Quick-Read Results

Gain actionable insights at a glance with:

  • Clinically significant results
  • Pertinent negative genomic variants
  • A therapy considerations summary
  • Flagged potential cancer-associated hereditary variants

THERAPY CONSIDERATIONS

Start to formulate a plan with:

  • Full-label indications
  • Treatment setting and approval status
  • Guideline evidence
  • Emerging clinical benefits

MARKER DETAILS

See the bigger picture with:

  • Full biomarker details
  • Gene, variant and prevalence information

Clinical Trial Options

Expand your patient’s options with:

  • Number of trial matches per marker
  • Clinical significance for matched trials
  • Highly-expressed/positive immune genes with trials
Omniseq Sample report
Omniseq Sample report
Sample requirements (include pathology report)

Formalin fixed paraffin embedded (FFPE) tissue

  • Resection specimens
  • Needle core biopsy specimens
  • Cell blocks from fine needle aspirates (FNAs)

**Do not submit decalcified specimens, cytology smears or samples from hematologic malignancies**

FFPE block (preferred) or 20 unbaked, positively charged, unstained slides cut a 5 µm plus one H&E
Turnaround time: 12-14 Days


See test menu for additional information

Lab Coat Icon

OmniSeq High Laboratory Quality Standards

  • NYS CLEP approved
  • ISO 13485 (2016) certified
  • CLIA and CAP accredited
Coverage

Labcorp Broad National Coverage

  • In-network with most major health plans
  • 1,600 contractual relationships with plans, payers and other healthcare organizations
References

1. OmniSeq Bioinformatics Knowledgebase - data curation January 2021.